替普利珠单抗调节两例自身免疫性多内分泌综合征1型患者2期1型糖尿病
本文报告两例自身免疫性多内分泌综合征1型(APS-1)合并2期1型糖尿病(T1D)青少年接受14天替普利珠单抗治疗的临床反应。两例血糖均改善,其中一例短暂需要胰岛素者在治疗后2周恢复胰岛素独立;一例胰腺体积短暂增加且循环淋巴细胞归巢受体和衰老标志物变化。非胰腺APS-1表现无变化。结论提示替普利珠单抗可能保护APS-1相关T1D的β细胞功能,需更大研究明确疗效、持久性及免疫和组织机制。
要点
- 两例APS-1合并2期T1D青少年接受14天替普利珠单抗后血糖均改善。
- 一例短暂需胰岛素者治疗后2周恢复胰岛素独立。
- 一例胰腺体积短暂增加,循环淋巴细胞归巢受体和衰老标志物变化。
核心结论
- 替普利珠单抗可能保护APS-1相关T1D的β细胞功能。
- 需更大研究明确该罕见背景下替普利珠单抗的疗效、持久性及免疫和组织机制。
研究设计与样本
- 报告两例APS-1合并2期T1D青少年接受14天替普利珠单抗疗程的临床反应。
- 其中一例在治疗前后进行胰腺MRI和光谱免疫细胞表型分析。
主要发现
- 两例患者血糖均改善。
- 一例短暂需要胰岛素者在治疗后2周恢复胰岛素独立。
- 接受检测的个体胰腺体积短暂增加,循环淋巴细胞归巢受体和衰老标志物变化。
- 非胰腺APS-1表现无变化。
临床怎么用
- 对于APS-1合并2期T1D患者,替普利珠单抗可能作为保护β细胞功能的治疗选择,但需更大研究验证。
局限性
- 仅报告两例患者,样本量小。
- 替普利珠单抗在APS-1相关糖尿病中的疗效、持久性及免疫和组织机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoimmune polyendocrine syndrome type 1 (APS-1) is a rare, monogenic autoimmune disorder that may manifest as type 1 diabetes (T1D). Teplizumab, an anti-CD3 monoclonal antibody, delays progression of stage 2 T1D, but its effects in APS-1-associated diabetes are unknown. RESEARCH DESIGN AND METHODS: We report clinical responses of two adolescents with APS-1 and stage 2 T1D who received 14-day courses of teplizumab. In one patient, pancreatic MRI and spectral immune cell phenotyping were performed before and after treatment. RESULTS: Both patients exhibited improved glycemia. One who briefly required insulin recovered insulin independence 2 weeks after therapy. Pancreatic volume transiently increased, and circulating lymphocytes showed changes in homing receptors and senescence markers in the individual who underwent those studies. Nonpancreatic APS-1 manifestations were unchanged. CONCLUSIONS: Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.
引用
- Wilson CS, Falk A, Williams JM, et al. Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1. Diabetes Care. 2026. PMID: 41223156. doi:10.2337/dc25-1444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。